ArticleEvidence-based complementary and alternative medicine : eCAM2011
Biochanin a, a phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4, suppresses ovalbumin-induced airway hyperresponsiveness.
Article in Evidence-based complementary and alternative medicine : eCAM, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Large-scale comparative virtual screening identifies novel molecular targets underlying the multi-target activity of quercetin in psoriasis.Inflammopharmacology · 2026Article
- Mechanisms Behind the Pharmacological Application of Biochanin-A: A review.F1000Research · 2023Review
- Activity of isoflavone biochanin A in chronic experimental toxoplasmosis: impact on inflammation.Parasitology research · 2022Article
- Bioinformatics andBioengineered · 2021Article
- Biochanin A Regulates Key Steps of Inflammation Resolution in a Model of Antigen-Induced Arthritis via GPR30/PKA-Dependent Mechanism.Frontiers in pharmacology · 2021Article
- Biochanin A alleviates gingival inflammation and alveolar bone loss in rats with experimental periodontitis.Experimental and therapeutic medicine · 2020Article
- Biochanin A attenuates zymosan-induced arthritis in mice similarly to 17-β estradiol: an alternative to hormone replacement therapy?Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2020Article
- Molecular Targets of Natural Products for Chondroprotection in Destructive Joint Diseases.International journal of molecular sciences · 2020Review
- Advances in Pharmacological Actions and Mechanisms of Flavonoids from Traditional Chinese Medicine in Treating Chronic Obstructive Pulmonary Disease.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Perspectives Regarding the Role of Biochanin A in Humans.Frontiers in pharmacology · 2019Review
- Biochanin A extirpates the epithelial-mesenchymal transition in a human lung cancer.Experimental and therapeutic medicine · 2018Article
- Biochanin A inhibits lipopolysaccharide-induced inflammatory cytokines and mediators production in BV2 microglia.Neurochemical research · 2015Article
- Protective effects of biochanin A on articular cartilage: in vitro and in vivo studies.BMC complementary and alternative medicine · 2014Article
- The effects of cocoa on the immune system.Frontiers in pharmacology · 2013Article
- The Immunomodulatory Effect of You-Gui-Wan on Dermatogoides-pteronyssinus-Induced Asthma.Evidence-based complementary and alternative medicine : eCAM · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigated the potential of biochanin A, a phytoestrogenic isoflavone of red clover (Triflolium pratense), for use in treating asthma or chronic obstructive pulmonary disease (COPD). Biochanin A (100 μmol/kg, orally (p.o.)) significantly attenuated airway resistance (R(L)), enhanced pause (P(enh)), and increased lung dynamic compliance (C(dyn)) values induced by methacholine (MCh) in sensitized and challenged mice. It also significantly suppressed an increase in the number of total inflammatory cells, neutrophils, and eosinophils, and levels of cytokines, including interleukin (IL)-2, IL-4, IL-5, and tumor necrosis factor (TNF)-α in bronchoalveolar lavage fluid (BALF) of the mice. However, it did not influence interferon (IFN)-γ levels. Biochanin A (100 μmol/kg, p.o.) also significantly suppressed the total and ovalbumin (OVA)-specific immunoglobulin E (IgE) levels in the serum and BALF, and enhanced the total IgG(2a) level in the serum of these mice. The PDE4(H)/PDE4(L) value of biochanin A was calculated as >35. Biochanin A did not influence xylazine/ketamine-induced anesthesia. Biochanin A (10~30 μM) significantly reduced cumulative OVA (10~100 μg/mL)-induced contractions in the isolated guinea pig trachealis, suggesting that it inhibits degranulation of mast cells. In conclusion, red clover containing biochanin A has the potential for treating allergic asthma and COPD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.